Evaluation of ocular and genetic findings in patients with Neurofibromatosis Type 1

Abstract views: 74 / PDF downloads: 71





Genetic Analyzes, Neurofibromatosis Type 1, Ophthalmology


Neurofibromatosis type 1 (NF1) is an autosomal dominantly inherited disease affecting multiple organ systems and showing many different clinical symptoms. The severity of the disease varies from person to person and progresses gradually over the years. In this study, 17 NF1 patients who had a definite diagnosis were evaluated in terms of genetic, ophthalmological, and nervous system investigations. Approximately 5000 patients who visited medical genetics clinic between 2012 and 2022 are recorded in our archive. In 17 of these patients, a definitive genetic diagnosis was made. In the course of the study, the researchers collected some clinical parameters such as antenatal, intrapartum, and postpartum history and family history. In the family history, the researchers did a detailed pedigree with at least 3 generations of analysis, questioned parental kinship, looked for similar members in families, and identified inheritance patterns of the disorder. Peripheral venous blood samples were taken from the patients and sent to a commercial laboratory for gene panels or WES while the karyotyping was carried out in our laboratory. After obtaining the definitive genetic diagnosis of all patients, we compiled a table with the other parameters we questioned. This study presented the genotype and phenotype findings of NF1 patients. Ophthalmological symptoms in patients were also examined. These new-generation genetic disease diagnosis methods can be routinely used in clinical practice by medical geneticists. The diagnosis of a disease is one step ahead of its treatment. Because if the necessary diagnosis is not made, treatment of the disease is not possible. While this situation was more difficult in the past, nowadays, with the developing technology, diseases can be diagnosed more easily. In NF1 disease, more information can be obtained as a result of genetics, imaging, and examinations of other branches.


Download data is not yet available.


Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Prim. 2017;3(1):1-17.

Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol. 2009;61(1):1-14.

Yap Y-S, McPherson JR, Ong C-K, et al. The NF1 gene revisited–from bench to bedside. Oncotarget. 2014;5(15):5873.

Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science (80- ). 1990;249(4965):181-186.

Maruoka R, Takenouchi T, Torii C, et al. The use of next-generation sequencing in molecular diagnosis of neurofibromatosis type 1: a validation study. Genet Test Mol Biomarkers. 2014;18(11):722-735.

Woodward LM. Ocular manifestations of phakomatoses. Int Ophthalmol Clin. 2014;54(3):105-110.

Lubs M-LE, Bauer MS, Formas ME, Djokic B. Lisch nodules in neurofibromatosis type 1. N Engl J Med. 1991;324(18):1264-1266.

Boley S, Sloan JL, Pemov A, Stewart DR. A quantitative assessment of the burden and distribution of Lisch nodules in adults with neurofibromatosis type 1. Invest Ophthalmol Vis Sci. 2009;50(11):5035-5043.

Weleber RG, Zonana J. Iris hamartomas (Lisch nodules) in a caseCase of segmental neurofibromatosis. Am J Ophthalmol. 1983;96(6):740-743.

Chernoff KA, Schaffer J V. Cutaneous and ocular manifestations of neurocutaneous syndromes. Clin Dermatol. 2016;34(2):183-204.

Abdolrahimzadeh S, Plateroti AM, Recupero SM, Lambiase A. An update on the ophthalmologic features in the phakomatoses. J Ophthalmol. 2016;2016.

Kinori M, Hodgson N, Zeid JL. Ophthalmic manifestations in neurofibromatosis type 1. Surv Ophthalmol. 2018;63(4):518-533.

Laue L, Comite F, Hench K, Loriaux DL, Cutler GB, Pescovitz OH. Precocious puberty associated with neurofibromatosis and optic gliomas: treatment with luteinizing hormone releasing hormone analogue. Am J Dis Child. 1985;139(11):1097-1100.

Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis‐1: controversies and recommendations. Ann Neurol Off J Am Neurol Assoc Child Neurol Soc. 2007;61(3):189-198.

Cassiman C, Legius E, Spileers W, Casteels I. Ophthalmological assessment of children with neurofibromatosis type 1. Eur J Pediatr. 2013;172:1327-1333.

Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86(5):747-754.

Kestle JRW, Hoffman HJ, Mock AR. Moyamoya phenomenon after radiation for optic glioma. J Neurosurg. 1993;79(1):32-35.

Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44(2):81-88.

Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1–associated human and mouse brain tumors. Cancer Res. 2005;65(7):2755-2760.

Weiss B, Widemann BC, Wolters P, et al. Sirolimus for progressive neurofibromatosis type 1–associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015;17(4):596-603.

Robertson KA, Nalepa G, Yang F-C, et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol. 2012;13(12):1218-1224.

Ober RR, Palmer EA, Drack A V, Wright KW. Retinopathy of prematurity. Handb Pediatr Retin Dis. Published online 2006:284-349.

Grant WM, Walton DS. Distinctive gonioscopic findings in glaucoma due to neurofibromatosis. Arch Ophthalmol. 1968;79(2):127-134.


Shaheen BS, Bakir M, Jain S. Corneal nerves in health and disease. Surv Ophthalmol. 2014;59(3):263-285.

Rescaldani C, Nicolini P, Fatigati G, Bottoni FG. Clinical application of digital indocyanine green angiography in choroidal neurofibromatosis. Ophthalmologica. 1998;212(2):99-104.

Destro M, D’amico DJ, Gragoudas ES, et al. Retinal manifestations of neurofibromatosis: diagnosis and management. Arch Ophthalmol. 1991;109(5):662-666.

Nussbaum RL, McInnes RR, Willard HF. Thompson & Thompson Genetics in Medicine E-Book. Elsevier Health Sciences; 2015.

Zhang J, Tong H, Fu X, et al. Molecular characterization of NF1 and neurofibromatosis type 1 genotype-phenotype correlations in a Chinese population. Sci Rep. 2015;5(1):11291.

Thomson SAM, Fishbein L, Wallace MR. NF1 mutations and molecular testing. J Child Neurol. 2002;17(8):555-561.

Pros E, Gómez C, Martín T, Fábregas P, Serra E, Lázaro C. Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations. Hum Mutat. 2008;29(9):E173-E193.

Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-423.

Evans DG, Bowers N, Burkitt-Wright E, et al. Comprehensive RNA analysis of the NF1 gene in classically affected NF1 affected individuals meeting NIH criteria has high sensitivity and mutation negative testing is reassuring in isolated caseCases with pigmentary features only. EBioMedicine. 2016;7:212-220.

Gurovich Y, Hanani Y, Bar O, et al. Identifying facial phenotypes of genetic disorders using deep learning. Nat Med. 2019;25(1):60-64.

Mishima H, Suzuki H, Doi M, et al. Evaluation of Face2Gene using facial images of patients with congenital dysmorphic syndromes recruited in Japan. J Hum Genet. 2019;64(8):789-794.

Rosenbaum T, Engelbrecht V, Krölls W, van Dorsten FA, Hoehn-Berlage M, Lenard H-G. MRI abnormalities in neurofibromatosis type 1 (NF1): a study of men and mice. Brain Dev. 1999;21(4):268-273.

Sabbagh A, Pasmant E, Laurendeau I, et al. Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Hum Mol Genet. 2009;18(15):2768-2778.

Marco SBS, Pisón JL, Escribano CC, Viejo IG, Gallart MDM, Villagrasa PS. Neurological manifestations of neurofibromatosis type 1: our experience. Neurol (English Ed. 2022;37(5):325-333.

Keleşoğlu KS, Keskin S, Sivri M, Erdoğan H, Nayman A, Koplay M. Nörofibromatozis tip 1: Kraniyal MRG Bulguları. Published online 2014.

Parkhurst E, Abboy S. Optic gliomas in neurofibromatosis type 1. J Pediatr Ophthalmol Strabismus. 2016;53(6):334-338.

Abaloun Y, Ajhoun Y. Lisch nodule in neurofibromatosis type 1. Pan Afr Med J. 2017;27:218.

Garg S, Green J, Leadbitter K, et al. Neurofibromatosis type 1 and autism spectrum disorder. Pediatrics. 2013;132(6):e1642-e1648.




How to Cite

Eroğul, Özgür, Elmas, M., Demir, A. N., & Mat, E. (2024). Evaluation of ocular and genetic findings in patients with Neurofibromatosis Type 1. HEALTH SCIENCES QUARTERLY, 4(1), 61–72. https://doi.org/10.26900/hsq.2142



Original Article

Most read articles by the same author(s)